KLOW is the market name for a research peptide blend that combines four distinct peptides in a single lyophilized vial: GHK-Cu, BPC-157, TB-500 (a thymosin β4 fragment) and KPV. Each has its own separately documented preclinical biology, and the rationale for combining them rests on complementary mechanisms rather than proven clinical synergy. A full referenced write-up lives in our separate KLOW monograph; this article is a component-by-component explainer for researchers. The blend itself ships as KLOW Blend , an 80 mg vial, ≥98–99% purity by HPLC (high-performance liquid chromatography, a purity-testing method), for laboratory research only.
What is in the KLOW blend
The four components belong to different structural classes of peptides and are associated in the literature with different tissue-repair and inflammation-control processes:
| Component | What it is | Direction documented in the literature |
|---|---|---|
| GHK-Cu | Gly-His-Lys tripeptide complexed with copper(II) | extracellular-matrix remodeling, collagen/elastin synthesis, antioxidant effects |
| BPC-157 | stable gastric pentadecapeptide (15 amino acids) | angiogenesis, NO-system interaction, mucosal protection and connective-tissue healing |
| TB-500 | synthetic thymosin β4 fragment with the LKKTET motif | actin sequestration, cell migration, wound healing |
| KPV | Lys-Pro-Val C-terminal tripeptide of the α-MSH hormone | NF-κB suppression, intestinal anti-inflammatory activity |
GHK-Cu: the copper tripeptide
GHK is a natural tripeptide (glycyl-L-histidyl-L-lysine) that forms a stable coordination complex with a copper(II) ion; it is typically studied in exactly this form, as GHK-Cu. In the preclinical literature the copper complex is associated with stimulating collagen and elastin synthesis, remodeling the extracellular matrix and antioxidant effects , in part by delivering copper as a cofactor to enzymes such as lysyl oxidase [1]. Review work describes GHK acting on numerous cellular pathways involved in skin regeneration, from activating repair genes to modulating inflammation [2]. Historically the peptide was isolated from human plasma as a factor that changes how tissues behave during remodeling, and whose level declines with age [3]. Importantly, all of this evidence comes from cell and animal models, not from controlled clinical trials of the blend itself.
BPC-157: the stable pentadecapeptide
BPC-157 is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV) derived from a protective protein found in gastric juice , hence the name “body protection compound”. It is most thoroughly characterized in gastrointestinal models, where it is linked to mucosal protection and accelerated healing [4]. A separate line of preclinical work concerns connective tissue: in a cell-culture and animal study, BPC-157 accelerated tendon healing by promoting cell outgrowth, survival and fibroblast migration [5]. Mechanistically these effects are frequently tied to angiogenesis and interaction with standard angiogenic growth factors (the VEGFR2 pathway), as described in comparative reviews of tendon, ligament, muscle and bone healing [6]. More recent systematic reviews summarize the peptide’s role in accelerating musculoskeletal soft-tissue healing while stressing that the overwhelming majority of the data is preclinical [7]. BPC-157 is usually what drives demand for blends like this, so it is worth emphasizing: controlled human trials confirming these effects are currently lacking.
TB-500 (a thymosin β4 fragment)
The trade name TB-500 usually refers to a synthetic fragment of thymosin β4 , a small regulatory protein with a central LKKTET motif whose main biochemical function is sequestering monomeric actin and regulating cytoskeletal dynamics. Reviews characterize thymosin β4 as a multi-functional regenerative peptide with documented effects on cell migration, angiogenesis and tissue repair [8]. In experimental skin models, thymosin β4 accelerated wound healing and stimulated cell migration [9]. One of the most-cited studies showed that in a cardiac model the peptide activates integrin-linked kinase (ILK) and promotes myocardial cell migration and survival with signs of cardioprotection [10]. As with the other components, this is preclinical work; TB-500 is not an approved drug.
KPV: the anti-inflammatory tripeptide
KPV (lysine-proline-valine) is the C-terminal tripeptide of the α-melanocyte-stimulating hormone (α-MSH). Unlike the three preceding components, which are oriented mainly toward tissue repair, KPV is studied in the literature primarily as an anti-inflammatory fragment. A classic study showed that KPV is taken up by intestinal epithelium via the PepT1 transporter and reduces inflammation by suppressing the NF-κB signaling pathway [11]. Independent studies in murine models of inflammatory bowel disease (IBD) confirmed the anti-inflammatory potential of this melanocortin-derived tripeptide [12]. Within the blend, KPV adds an “anti-inflammatory arm” that is mechanistically distinct from the reparative effects of GHK-Cu, BPC-157 and TB-500.
Why combine them into one blend
The logic of KLOW is not that four peptides hit a single target, but that their documented mechanisms cover different stages of repair and inflammation control: angiogenesis and mucosal protection (BPC-157), cell migration and cytoskeletal dynamics (TB-500), matrix remodeling and collagen synthesis (GHK-Cu), and suppression of pro-inflammatory signaling (KPV). Proponents of such blends hypothesize that the combination may span a broader set of processes than any single peptide alone. But this is a hypothesis, not an established fact: no controlled clinical trials of the KLOW blend itself exist, and the evidence for the individual components is largely preclinical. Any claim of “synergy” should be read in exactly that light.
What the research does not yet show
To read the data honestly, keep one key limitation in mind: almost all of the results cited above are individual peptides in individual preclinical models. That does not imply that the effects survive in a fixed mixture, that doses which “worked” in animals transfer to any other context, or that the four mechanisms simply add up without influencing one another. The pharmacokinetics of the blend itself , how the components behave together in solution and over time , have not been described in the literature. Nor is there data on whether the components compete for shared uptake routes (for example PepT1 for KPV). KLOW is therefore best treated as a tool for testing the complementarity hypothesis, not as a compound with a proven combined effect.
Handling, storage and reconstitution
All four peptides are supplied as a single shared lyophilized powder. Standard laboratory handling practices:
- Storing the lyophilizate: in a dry, light-protected place; for long-term storage, at −20 °C. Avoid moisture.
- Reconstitution: sterile or bacteriostatic laboratory water; add the water down the vial wall without harsh shaking.
- After reconstitution: store at +2…+8 °C; avoid repeated freeze-thaw cycles.
- GHK-Cu caveat: the copper complex is sensitive to reducing agents and chelators , keep them out of the solution.
Purity and batch control
Reproducible research depends not solely on how you handle the material but on its input quality. KLOW Blend ships at ≥98–99% purity by HPLC, and every batch is HPLC-checked , a certificate of analysis (COA) is tied to the specific lot. For a blend this matters even more: the correct ratio of the four components in the vial is set during manufacturing and cannot be verified “by eye”, so documented batch control is the only practical way to know the composition of what you are working with.
You can work out the solvent volume for a target concentration with our reconstitution calculator; see the vial spec and price on the KLOW Blend page, and the full referenced scientific write-up in the monograph.
Disclaimer: research use only
This material is compiled from publicly available scientific sources and provided for reference purposes only. It is not medical advice, a usage recommendation or a dosing instruction. GHK-Cu, BPC-157, TB-500 and KPV are experimental compounds that are not approved medicines; the KLOW blend has not undergone controlled clinical trials. All products mentioned on this site are supplied strictly for laboratory research and are not intended for human or animal consumption, nor for diagnostic or therapeutic use.
The full list of sources with links, is in the monograph: KLOW.
